Tech Company Financing Transactions
Ancilia Biosciences Funding Round
On 8/28/2024, Ancilia Biosciences raised $4.2 million in funding from Safar & Partners, Metaplanet and PsyMed Ventures.
Transaction Overview
Company Name
Announced On
8/28/2024
Transaction Type
Venture Equity
Amount
$4,200,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to expand operations and its R&D sector.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
3960 Broadway, 6th Floor, Alexandria Launchlabs
New York, NY 10032
USA
New York, NY 10032
USA
Phone
Undisclosed
Website
Email Address
Overview
Ancilia is harnessing the natural power of CRISPR ?to create beneficial bacterial products with immunity against destructive viruses. Beneficial bacteria have ?broad potential to transform the treatment of a number of diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Alexandra Sakatos
Browse more venture capital transactions:
Prev: 8/28/2024: Pryzm Dynamics venture capital transaction
Next: 8/28/2024: Curio Digital Therapeutics venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. All VC database entries reported here come from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs